AU2663799A - Gene transfer-mediated angiogenesis therapy and techniques for intravascular gene delivery - Google Patents
Gene transfer-mediated angiogenesis therapy and techniques for intravascular gene delivery Download PDFInfo
- Publication number
- AU2663799A AU2663799A AU26637/99A AU2663799A AU2663799A AU 2663799 A AU2663799 A AU 2663799A AU 26637/99 A AU26637/99 A AU 26637/99A AU 2663799 A AU2663799 A AU 2663799A AU 2663799 A AU2663799 A AU 2663799A
- Authority
- AU
- Australia
- Prior art keywords
- vector
- histamine
- fgf
- protein
- artery
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000623 proteins and genes Proteins 0.000 title claims description 148
- 238000000034 method Methods 0.000 title claims description 76
- 230000033115 angiogenesis Effects 0.000 title claims description 22
- 238000012546 transfer Methods 0.000 title description 83
- 238000001476 gene delivery Methods 0.000 title description 26
- 230000001404 mediated effect Effects 0.000 title description 8
- 238000002560 therapeutic procedure Methods 0.000 title description 4
- 239000013598 vector Substances 0.000 claims description 103
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical group NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 72
- 238000002347 injection Methods 0.000 claims description 55
- 239000007924 injection Substances 0.000 claims description 55
- 108010074415 Angiogenic Proteins Proteins 0.000 claims description 54
- 108700019146 Transgenes Proteins 0.000 claims description 53
- 102000008076 Angiogenic Proteins Human genes 0.000 claims description 50
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 claims description 49
- 210000004351 coronary vessel Anatomy 0.000 claims description 47
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 claims description 41
- 241000701161 unidentified adenovirus Species 0.000 claims description 41
- 239000002550 vasoactive agent Substances 0.000 claims description 36
- 229960001340 histamine Drugs 0.000 claims description 35
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 33
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 31
- 239000013603 viral vector Substances 0.000 claims description 31
- 230000014509 gene expression Effects 0.000 claims description 30
- 102000004169 proteins and genes Human genes 0.000 claims description 30
- 210000004165 myocardium Anatomy 0.000 claims description 26
- 239000002245 particle Substances 0.000 claims description 22
- 239000003453 histamine agonist Substances 0.000 claims description 20
- 230000010076 replication Effects 0.000 claims description 20
- 210000001367 artery Anatomy 0.000 claims description 19
- 230000002950 deficient Effects 0.000 claims description 17
- 238000001802 infusion Methods 0.000 claims description 16
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 claims description 15
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 14
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 14
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 claims description 13
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims description 13
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 claims description 13
- 238000001727 in vivo Methods 0.000 claims description 13
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 11
- 210000001105 femoral artery Anatomy 0.000 claims description 10
- 238000011161 development Methods 0.000 claims description 7
- 230000002792 vascular Effects 0.000 claims description 7
- 102000005604 Myosin Heavy Chains Human genes 0.000 claims description 6
- 108010084498 Myosin Heavy Chains Proteins 0.000 claims description 6
- 102000030621 adenylate cyclase Human genes 0.000 claims description 6
- 108060000200 adenylate cyclase Proteins 0.000 claims description 6
- 230000002093 peripheral effect Effects 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 5
- 210000003752 saphenous vein Anatomy 0.000 claims description 5
- 108091006024 signal transducing proteins Proteins 0.000 claims description 5
- 102000034285 signal transducing proteins Human genes 0.000 claims description 5
- 210000001349 mammary artery Anatomy 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 210000001567 regular cardiac muscle cell of ventricle Anatomy 0.000 claims description 4
- 108091006027 G proteins Proteins 0.000 claims description 3
- 102000030782 GTP binding Human genes 0.000 claims description 3
- 108091000058 GTP-Binding Proteins 0.000 claims description 3
- 108091005682 Receptor kinases Proteins 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 238000001361 intraarterial administration Methods 0.000 claims description 3
- 229940043355 kinase inhibitor Drugs 0.000 claims description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 3
- 108020003175 receptors Proteins 0.000 claims description 3
- 102000005962 receptors Human genes 0.000 claims description 3
- 101000629029 Homo sapiens Myosin regulatory light chain 2, ventricular/cardiac muscle isoform Proteins 0.000 claims description 2
- 102100026925 Myosin regulatory light chain 2, ventricular/cardiac muscle isoform Human genes 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 58
- 230000003612 virological effect Effects 0.000 description 33
- 241001465754 Metazoa Species 0.000 description 32
- 210000002216 heart Anatomy 0.000 description 28
- 101150066555 lacZ gene Proteins 0.000 description 24
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 23
- 208000031225 myocardial ischemia Diseases 0.000 description 22
- 239000013612 plasmid Substances 0.000 description 22
- 230000017531 blood circulation Effects 0.000 description 21
- 230000000302 ischemic effect Effects 0.000 description 21
- 230000002107 myocardial effect Effects 0.000 description 18
- 238000011282 treatment Methods 0.000 description 18
- 238000001415 gene therapy Methods 0.000 description 16
- 210000004413 cardiac myocyte Anatomy 0.000 description 15
- 230000004087 circulation Effects 0.000 description 15
- 239000000203 mixture Substances 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 108010016628 ameroid Proteins 0.000 description 12
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 108010076504 Protein Sorting Signals Proteins 0.000 description 11
- 230000000747 cardiac effect Effects 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 241000700605 Viruses Species 0.000 description 10
- 230000001746 atrial effect Effects 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 210000002027 skeletal muscle Anatomy 0.000 description 9
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 8
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 8
- 208000019622 heart disease Diseases 0.000 description 8
- 208000028867 ischemia Diseases 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 208000018262 Peripheral vascular disease Diseases 0.000 description 7
- 230000002491 angiogenic effect Effects 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 7
- 229940126864 fibroblast growth factor Drugs 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 241001135569 Human adenovirus 5 Species 0.000 description 6
- 241000282887 Suidae Species 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 210000000107 myocyte Anatomy 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- 108091033319 polynucleotide Proteins 0.000 description 6
- 102000040430 polynucleotide Human genes 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 230000000644 propagated effect Effects 0.000 description 6
- 230000006798 recombination Effects 0.000 description 6
- 238000005215 recombination Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000008719 thickening Effects 0.000 description 6
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 5
- 210000000709 aorta Anatomy 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000036770 blood supply Effects 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000004064 dysfunction Effects 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 102000058223 human VEGFA Human genes 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000007431 microscopic evaluation Methods 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 230000003248 secreting effect Effects 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 238000005199 ultracentrifugation Methods 0.000 description 5
- 206010002383 Angina Pectoris Diseases 0.000 description 4
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 4
- 108700008625 Reporter Genes Proteins 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000008488 polyadenylation Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000013605 shuttle vector Substances 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 101100077213 Caenorhabditis elegans mlc-2 gene Proteins 0.000 description 3
- 241000702421 Dependoparvovirus Species 0.000 description 3
- 108090000382 Fibroblast growth factor 6 Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000002592 echocardiography Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000004217 heart function Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000005246 left atrium Anatomy 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000003362 replicative effect Effects 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000008728 vascular permeability Effects 0.000 description 3
- XDKYTXBAVJELDQ-UHFFFAOYSA-N 2-methylhistamine Chemical compound CC1=NC=C(CCN)N1 XDKYTXBAVJELDQ-UHFFFAOYSA-N 0.000 description 2
- XPQIPUZPSLAZDV-UHFFFAOYSA-N 2-pyridylethylamine Chemical compound NCCC1=CC=CC=N1 XPQIPUZPSLAZDV-UHFFFAOYSA-N 0.000 description 2
- 108060003345 Adrenergic Receptor Proteins 0.000 description 2
- 102000017910 Adrenergic receptor Human genes 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000557626 Corvus corax Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101150092822 FGF5 gene Proteins 0.000 description 2
- 102100028075 Fibroblast growth factor 6 Human genes 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- TWZOYAWHWDRMEZ-UHFFFAOYSA-N Thiazolylethylamine Chemical compound NCCC1=NC=CS1 TWZOYAWHWDRMEZ-UHFFFAOYSA-N 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000002870 angiogenesis inducing agent Substances 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- UUQMNUMQCIQDMZ-UHFFFAOYSA-N betahistine Chemical compound CNCCC1=CC=CC=N1 UUQMNUMQCIQDMZ-UHFFFAOYSA-N 0.000 description 2
- 229960004536 betahistine Drugs 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000000157 blood function Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000001174 endocardium Anatomy 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 210000005003 heart tissue Anatomy 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229940100630 metacresol Drugs 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- 238000011422 pharmacological therapy Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 101150086745 pre gene Proteins 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000004895 regional blood flow Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 230000000250 revascularization Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000007492 two-way ANOVA Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 101150029062 15 gene Proteins 0.000 description 1
- YQNRVGJCPCNMKT-LFVJCYFKSA-N 2-[(e)-[[2-(4-benzylpiperazin-1-ium-1-yl)acetyl]hydrazinylidene]methyl]-6-prop-2-enylphenolate Chemical compound [O-]C1=C(CC=C)C=CC=C1\C=N\NC(=O)C[NH+]1CCN(CC=2C=CC=CC=2)CC1 YQNRVGJCPCNMKT-LFVJCYFKSA-N 0.000 description 1
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- 239000013607 AAV vector Substances 0.000 description 1
- 206010001258 Adenoviral infections Diseases 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 101100462537 Caenorhabditis elegans pac-1 gene Proteins 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 208000001778 Coronary Occlusion Diseases 0.000 description 1
- 201000000054 Coronary Restenosis Diseases 0.000 description 1
- 206010011086 Coronary artery occlusion Diseases 0.000 description 1
- 206010056489 Coronary artery restenosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 101150021185 FGF gene Proteins 0.000 description 1
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 102000003967 Fibroblast growth factor 5 Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000696272 Gull adenovirus Species 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101001060267 Homo sapiens Fibroblast growth factor 5 Proteins 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090000362 Lymphotoxin-beta Proteins 0.000 description 1
- 101100117764 Mus musculus Dusp2 gene Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000013534 Troponin C Human genes 0.000 description 1
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 description 1
- 102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 description 1
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000007978 cacodylate buffer Substances 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 210000001043 capillary endothelial cell Anatomy 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 230000009989 contractile response Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 230000002169 extracardiac Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- -1 for example Proteins 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 102000057233 human FGF5 Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 238000000424 optical density measurement Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000013310 pig model Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 108010017843 platelet-derived growth factor A Proteins 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000026341 positive regulation of angiogenesis Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000006884 regulation of angiogenesis Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000010967 transthoracic echocardiography Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000028973 vesicle-mediated transport Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Paints Or Removers (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2177398A | 1998-02-11 | 1998-02-11 | |
| US09021773 | 1998-02-11 | ||
| PCT/US1999/002702 WO1999040945A2 (en) | 1998-02-11 | 1999-02-09 | Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003204457A Division AU2003204457A1 (en) | 1998-02-11 | 2003-05-30 | Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2663799A true AU2663799A (en) | 1999-08-30 |
Family
ID=21806073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU26637/99A Abandoned AU2663799A (en) | 1998-02-11 | 1999-02-09 | Gene transfer-mediated angiogenesis therapy and techniques for intravascular gene delivery |
Country Status (11)
| Country | Link |
|---|---|
| EP (2) | EP1695719A1 (https=) |
| JP (1) | JP2002502885A (https=) |
| KR (1) | KR20010015915A (https=) |
| CN (2) | CN101186928A (https=) |
| AU (1) | AU2663799A (https=) |
| CA (1) | CA2320302A1 (https=) |
| EA (1) | EA019099B1 (https=) |
| IL (1) | IL137765A0 (https=) |
| NZ (1) | NZ545047A (https=) |
| WO (1) | WO1999040945A2 (https=) |
| ZA (1) | ZA991102B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001034208A1 (en) * | 1999-11-05 | 2001-05-17 | The Regents Of The University Of California | Techniques and compositions for treating cardiovascular disease by in vivo gene delivery |
| US6752987B1 (en) | 1995-02-28 | 2004-06-22 | The Regents Of The University Of California | Adenovirus encoding human adenylylcyclase (AC) VI |
| WO2000024415A2 (en) | 1998-10-28 | 2000-05-04 | Cornell Research Foundation, Inc. | Methods for regulating angiogenesis and vascular integrity using trk receptor ligands |
| EP1255822A2 (en) | 1999-12-27 | 2002-11-13 | The Regents Of The University Of California | Modified adenylylcyclase type vi useful in gene therapy for congestive heart failure |
| WO2002002148A2 (en) * | 2000-06-30 | 2002-01-10 | Collateral Therapeutics, Inc. | Dual recombinant gene therapy compositions and methods of use |
| JP2005052001A (ja) * | 2001-07-05 | 2005-03-03 | Takara Bio Inc | 遺伝子治療剤 |
| DE602006017071D1 (de) | 2005-01-25 | 2010-11-04 | Five Prime Therapeutics Inc | Zusammensetzungen und verfahren zur behandlung von herzkrankheiten |
| GB2437893A (en) * | 2006-07-25 | 2007-11-07 | Celladon Corp | Extended antegrade epicardial coronary infusion of adeno-associated viral vectors for gene therapy |
| US8157760B2 (en) | 2007-07-18 | 2012-04-17 | Silk Road Medical, Inc. | Methods and systems for establishing retrograde carotid arterial blood flow |
| WO2009105135A1 (en) | 2008-02-19 | 2009-08-27 | Celladon Corporation | Compositions for enhanced uptake of viral vectors in the myocardium |
| US20130096500A1 (en) * | 2011-07-07 | 2013-04-18 | Gabor Rubanyi | Nucleic acid based cardiovascular therapeutics |
| US20140296769A1 (en) * | 2013-03-28 | 2014-10-02 | Silk Road Medical, Inc. | Methods and Systems for Establishing Retrograde Carotid Arterial Blood Flow |
| WO2019089385A1 (en) | 2017-11-02 | 2019-05-09 | Silk Road Medical, Inc. | Fenestrated sheath for embolic protection during transcarotid carotid artery revascularization |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA001616B1 (ru) * | 1995-02-28 | 2001-06-25 | Зе Риджентс Оф Зи Юнивесити Оф Кэлифоньэ | Способ лечения болезни сердца, способ лечения недостаточности периферических сосудов и способ ограничения доставки и экспрессии трансгенной конструкции в определенном органе или структуре |
| US5869230A (en) * | 1995-03-30 | 1999-02-09 | Beth Israel Hospital Association | Gene transfer into the kidney |
| WO1999017807A1 (en) * | 1997-10-08 | 1999-04-15 | Cobra Therapeutics Ltd. | Use of a vasoactive compound in the enhancement of gene delivery |
| US6376471B1 (en) * | 1997-10-10 | 2002-04-23 | Johns Hopkins University | Gene delivery compositions and methods |
-
1999
- 1999-02-09 JP JP2000531196A patent/JP2002502885A/ja active Pending
- 1999-02-09 EP EP05026675A patent/EP1695719A1/en not_active Withdrawn
- 1999-02-09 CA CA002320302A patent/CA2320302A1/en not_active Abandoned
- 1999-02-09 AU AU26637/99A patent/AU2663799A/en not_active Abandoned
- 1999-02-09 CN CNA2007101808364A patent/CN101186928A/zh active Pending
- 1999-02-09 EP EP99906814A patent/EP1053025A2/en not_active Withdrawn
- 1999-02-09 KR KR1020007008781A patent/KR20010015915A/ko not_active Ceased
- 1999-02-09 EA EA200000828A patent/EA019099B1/ru not_active IP Right Cessation
- 1999-02-09 IL IL13776599A patent/IL137765A0/xx unknown
- 1999-02-09 CN CNB998049425A patent/CN100350979C/zh not_active Expired - Fee Related
- 1999-02-09 WO PCT/US1999/002702 patent/WO1999040945A2/en not_active Ceased
- 1999-02-09 NZ NZ545047A patent/NZ545047A/en not_active IP Right Cessation
- 1999-02-11 ZA ZA9901102A patent/ZA991102B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1301181A (zh) | 2001-06-27 |
| ZA991102B (en) | 2000-03-31 |
| JP2002502885A (ja) | 2002-01-29 |
| EA200000828A1 (ru) | 2001-02-26 |
| WO1999040945A3 (en) | 1999-09-30 |
| CN101186928A (zh) | 2008-05-28 |
| NZ545047A (en) | 2009-05-31 |
| EP1695719A1 (en) | 2006-08-30 |
| CN100350979C (zh) | 2007-11-28 |
| IL137765A0 (en) | 2001-10-31 |
| KR20010015915A (ko) | 2001-02-26 |
| EA019099B1 (ru) | 2014-01-30 |
| WO1999040945A2 (en) | 1999-08-19 |
| CA2320302A1 (en) | 1999-08-19 |
| EP1053025A2 (en) | 2000-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5792453A (en) | Gene transfer-mediated angiogenesis therapy | |
| US6174871B1 (en) | Gene therapies for enhancing cardiac function | |
| US20090082293A1 (en) | Techniques and compositions for treating cardiovascular disease by in vivo gene delivery | |
| AU767662B2 (en) | Variants of the angiogenic factor vascular endothelial cell growth factor: VEGF | |
| AU784392B2 (en) | Techniques and compositions for treating cardiovascular disease by in vivo gene delivery | |
| EP1695719A1 (en) | Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery | |
| CA2289600C (en) | Techniques and compositions for treating heart failure and ventricular remodeling by in vivo delivery of angiogenic transgenes | |
| AU2006200170B2 (en) | Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery | |
| AU706050C (en) | Gene transfer-mediated angiogenesis therapy | |
| HK1094944A (en) | Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery | |
| AU2006235836A1 (en) | Gene transfer-mediated angiogenesis therapy | |
| AU4754199A (en) | Gene transfer-mediated angiogenesis therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |